Back to Stocks

HRTX

HERON THERAPEUTICS, INC. /DE/
2 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Heron Therapeutics is demonstrating a significant commercial pivot, with its acute care franchise emerging as a high-growth engine.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the top-line growth in acute care, Heron's financial health is under severe pressure from margin erosion and a mounting debt burden.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every HRTX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a crossroads, where strong product-level demand is clashing with structural financial headwinds. The achievement of permanent J-codes for its acute care products is a definitive win that validates the commercial model and provides a clear path for market penetration. However, the transition from a profitable quarter to a net loss highlights the fragility of the current cost structure and the impact of high-cost debt servicing. Investors must now weigh the long-term value of a decade-long patent shield against the immediate risks of margin compression and debt covenants. While the acute care trajectory is bullish, the overall corporate health depends on whether Heron can convert its market share gains into operating leverage before its $44.8 million cash cushion is depleted. The central tension remains whether the 'permanent' reimbursement status can outpace the 'permanent' pressure of its leveraged balance sheet.

Selected Quarter

Core Takeaway

Heron has successfully de-risked its reimbursement profile for acute care products, but is now battling a high-interest debt load and shrinking gross margins.

Investor Lens

The trade-off is between the high-conviction growth of the acute care franchise and the systemic risk of the leveraged balance sheet.

Watch Next

Compliance with minimum cash and EBITDA covenants under the Working Capital Facility Agreement.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 11

Gross margins fell from 78.3% to 69.4% due to supplier mix and inventory reserves.

margin compression
70%
bearishMay 11

Company swung from a net income of $2.6M to a net loss of $8.1M YoY.

earnings miss
60%
bullishMay 11

Acute care sales grew 32.3% following the securing of permanent Medicare J-codes.

guidance raise
50%
neutralMay 11

Refinanced debt via Working Capital Facility with high effective interest of 11.7%.

debt restructure
40%
bearishMay 11

Gross margins fell from 78.3% to 69.4% due to supplier mix and inventory reserves.

margin compression
70%
bearishMay 11

Company swung from a net income of $2.6M to a net loss of $8.1M YoY.

earnings miss
60%
bullishMay 11

Acute care sales grew 32.3% following the securing of permanent Medicare J-codes.

guidance raise
50%
neutralMay 11

Refinanced debt via Working Capital Facility with high effective interest of 11.7%.

debt restructure
40%

Filing History

10-QMay 11, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a crossroads, where strong product-level demand is clashing with structural financial headwinds. The achievement of permanent J-codes for its acute care products is a definitive win that validates the commercial model and provides a clear path for market penetration. However, the transition from a profitable quarter to a net loss highlights the fragility of the current cost structure and the impact of high-cost debt servicing. Investors must now weigh the long-term value of a decade-long patent shield against the immediate risks of margin compression and debt covenants. While the acute care trajectory is bullish, the overall corporate health depends on whether Heron can convert its market share gains into operating leverage before its $44.8 million cash cushion is depleted. The central tension remains whether the 'permanent' reimbursement status can outpace the 'permanent' pressure of its leveraged balance sheet.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.